Office: Cambridge, MA

Executive Assistant:
Lynette Badin
(617) 949-2182

Scott Requadt, JD, MBA
Managing Director

Scott Requadt, JD, MBA, is currently a Managing Director for Clarus.  Scott has 15+ years of operating and investment experience in the pharmaceutical industry.  Prior to joining Clarus in 2005, Scott was Director, Business Development of TransForm Pharmaceuticals, Inc until it was acquired by Johnson & Johnson. At TransForm, Scott had broad responsibility for business development, corporate development and legal activities, including managing the company’s intellectual property group.

Prior to TransForm, Scott practiced for several years as an M&A attorney at the NYC-based law firm of Davis Polk & Wardwell, where he represented numerous private equity, pharma and technology clients. Before that, Scott was a law clerk for a senior judge at the Supreme Court of Canada.  Scott holds a B.Com (Economics & Finance)from McGill University (First Class Honors), a J.D. from University of Toronto and most recently an MBA from Harvard Business School, where he was a Baker Scholar.

Mr. Requadt has been involved in multiple Clarus investments spanning therapeutics, medtech and diagnostics. He has also been involved in several structured R&D risk-sharing investments with large pharma partners as well as the acquisition of royalty interests in drugs such as ibrutinib.

Current Board Seats

Previous Board Seats

Biolex Therapeutics - Board Observer 

Catabasis Pharmaceuticals - (NASDAQ:CATB) Board Observer 

Link Medicine (acquired by AstraZeneca) - Board Observer 

Oxford Immunotec (NASDAQ:OXFD) - Board Observer 

TYRX (acquired by Medtronic)

Clarus Board Seats

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Private
Team: Scott Requadt

AvroBio

AVROBIO Inc., a leader in lentiviral-based gene therapies, is a clinical stage company developing transformative, life-changing therapies that have the potential to transform patients’ lives in a single dose. The catalyst for creating AVROBIO is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies. The patient’s own cells can be effectively modified to deliver novel genes to cure serious debilitating disease.

AvroBio Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Scott Requadt

Catabasis Pharmaceuticals, Inc. (NASDAQ: CATB)

Catabasis is an early stage biopharmaceutical company led by experienced entrepreneurs that is developing NCEs that incorporate, and amplify the beneficial effects of, OMEGA-3 fatty acids. It is advancing multiple proprietary small molecule candidates for the treatment of metabolic disease and inflammation.

Catabasis Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Scott Requadt

Delenex Therapeutics

Delenex Therapeutics AG is a Swiss biotech company developing antibody fragments for local/topical treatment of chronic and systemic treatment of acute diseases. Delenex was spun-off from ESBATech before its acquisition by Alcon in September 2009

Delenex Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Royalty Interest
Team: Robert W. Liptak
Scott Requadt
Nicholas J. Simon

Edev

Edev is a special purpose vehicle that has entered into an R&D project financing relationship with an undisclosed pharma company to finance multiple Phase 3 clinical trials for additional indications of an already-approved drug.

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Scott Requadt
Emmett Cunningham

ESBATech AG aquired by Alcon in September 2009

Privately-held ESBATech AG is a Zurich, Switzerland based drug discovery and development company focused on advancing antibody fragments for therapeutic applications.

ESBATech Website

Fund: Clarus Lifesciences III, L.P.
Sector: Biotechnology
Type: Public
Team: Scott Requadt

Essa Pharmaceuticals (NASDAQ: EPIX)

ESSA is a pharmaceutical company focused on the development of small molecule drugs for the treatment of cancer, with focus on advanced prostate cancer. ESSA is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR). The AR is required for the growth and survival of most prostate cancer; therefore, the AR N-terminal domain is an ideal target for next-generation hormone therapy.

Essa Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Private
Team: Scott Requadt
Nicholas Galakatos

Heptares Therapeutics, Ltd.

Heptares is a drug discovery company focused on the discovery of novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs). The Company is deploying its proprietary StaR™ technology principally against highly validated but currently difficult or intractable GPCR targets in several disease areas.

Heptares Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Royalty Interest
Team: Scott Requadt
Nicholas J. Simon

Imbruvica

Imbruvica is an oral BTK-inhibitor currently under development by Pharmacyclics and J&J for a wide variety of B-cell malignancies, including chronic lymphocytic leukemia(CLL) and mantle cell lymphoma (MCL). It is currently in 8 pivotal trials and multiple Ph 2 trials for various relapsed/refractory and front line settings. The drug has been granted three breakthrough designations by the FDA and was approved for relapsed/refractory MCL in November 2013.

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Public
Team: Scott Requadt
Nicholas J. Simon
Dennis Henner

Intercept Pharmaceuticals (NASDAQ: ICPT)

Intercept is focused on the development and commercialization of novel, small molecule therapeutics to treat chronic liver disease by leveraging its expertise in bile acid chemistry.  Its lead candidate, obaticholic acid (OCA), is an FXR agonist that is currently in pivotal trials for primary biliary cirrhosis (PBC), a chronic autoimmune liver disease.  OCA has received orphan designation for PBC in both the US and Europe.  OCA is also being evaluated in an NIH-sponsored trial for non-alcoholic steatohepatitis (NASH).

Intercept Website

Fund: Clarus Lifesciences II, L.P.
Sector: Diagnostics & Tools
Type: Public
Team: Scott Requadt
William Young
Nicholas Galakatos

NanoString Technologies, Inc. (NASDAQ: NSTG)

Nanostring is a commercial stage company and an emerging leader in the expression profiling market. Its lead product is the only system capable of highly multiplexed direct quantification of individual mRNAs in a biological sample without the use of enzymes or amplification. With sensitivity below a single copy of mRNA per cell, high accuracy, robust output, and simplified workflow, the Nanostring platform offers investigators the benefits of the accuracy of PCR with the ability to interrogate more genes (up to a thousand) that would traditionally not be possible with PCR . Unlike PCR or microarrays, the Nanostring technology affords digital results by directly imaging and counting mRNAs on solid support.

NanoString Website

Fund: Clarus Lifesciences I, L.P.
Sector: Diagnostics & Tools
Type: Public
Team: Scott Requadt
Kurt C. Wheeler

Oxford Immunotec, Ltd. (NASDAQ: OXFD)

Oxford Immunotec Ltd develops and sells clinical diagnostic products based on its patented, regulatory approved T-SPOT® technology. T-SPOT is a novel platform technology that opens up new ways of diagnosing and monitoring infections by providing a simple and extremely accurate method of studying a person’s cellular immune response to an infection. Oxford Immunotec’s first product T-SPOT®.TB, is a revolutionary new blood test for diagnosing Tuberculosis infection, offering unmatched sensitivity.

Oxford Website

Fund: Clarus Lifesciences II, L.P.
Sector: Biotechnology
Type: Defined Exit
Team: Robert W. Liptak
Scott Requadt
Kurt C. Wheeler
Dennis Henner
Michele Park
Emmett Cunningham

SFJ Pharmaceuticals, Inc.

SFJ Pharmaceuticals (SanFrancisco/Japan) serves as a clinical development specialty pharma company with a focus on obtaining product approval in Japan. Targeted candidates for development in Japan are low risk compounds that are already approved or have a high likelihood of approval in the US with projected Japan annual sales in excess of $100M. To date, SFJ has entered definitive agreements with two major global pharma companies to fund Phase 3 trials for oncology assets. Pre-determined milestone payments to SFJ shall be received on approval of the asset in pre-specified countries.

SFJ Pharmaceuticals Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Private
Team: Scott Requadt
Nicholas Galakatos
Emmett Cunningham

Taligen acquired by Alexion (ALXN) in January 2011

Taligen is a biopharmaceutical company focused on developing inhibitors of the complement system for a variety of therapeutic indications.

Fund: Clarus Lifesciences I, L.P.
Sector: Medical Device
Type: Private
Team: Scott Requadt
William Young

TyRx acquired by Medtronic, Inc. in January 2014

TyRx develops and commercializes proprietary, polymer-based, antibiotic-eluting medical products that prevent infection and capsular scar formation, two common morbidities associated with medical device implants.It currently has 3 FDA approved products including AIGIS CRMD, an antibiotic-eluting mesh envelope to prevent infections associated with the implantation of cardiac rhythm management devices (CRMDs) such as pacemakers and implantable defibrillators. The company launched AIGIS CRMD in the US in Q3 2008 with its own specialty sales force.

TyRx Website

Fund: Clarus Lifesciences I, L.P.
Sector: Biotechnology
Type: Public
Team: Scott Requadt

VBI Vaccines (NASDAQ: VBIV)

VBI is dedicated to the innovative formulation,development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. VBI’s innovative approach to vaccine development and growing pipeline address clear market opportunities and are designed to answer critical unmet medical needs

VBI is aprivately held company headquartered in Cambridge, Massachusetts, with research facilities in Ottawa, Canada.

VBI Website